Tarsus Pharmaceuticals, Inc. Common Stock
TARSTarsus Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for eye diseases, particularly those with high unmet medical needs. The company emphasizes the development of targeted treatments for conditions such as Demodex blepharitis, aiming to improve patient outcomes through novel pharmaceutical solutions.
Company News
Tarsus Pharmaceuticals will host a live webcast on November 4, 2025, to report its third quarter 2025 financial results and provide a corporate update. The company has FDA-approved XDEMVY for Demodex blepharitis and is developing additional treatments for eye care and infectious disease prevention.
Capricorn Fund Managers Ltd acquired 484,500 shares of Phreesia, valued at $11.4 million, representing 3.8% of their reportable assets under management. The investment comes as Phreesia reaches a milestone of first quarterly net income and plans to expand payment solutions.
DelveInsight's analysis predicts growth in the Lyme disease market from 2025-2034, driven by emerging therapies and increased healthcare spending, with new vaccine and prevention technologies in development.
Tarsus Pharmaceuticals plans to participate in two upcoming healthcare investment conferences in September 2025, showcasing its eye care and infectious disease prevention pipeline, including its FDA-approved XDEMVY® treatment for Demodex blepharitis.
Three biotech companies - Boston Scientific, Arcutis Biotherapeutics, and Tarsus Pharmaceuticals - show promising developments in medical devices and drug treatments, with potential for significant investor returns.
